CytomX醫療 CTMX 深 滬
已收盤 10-31 16:00:00 美东时间
3.57
+0.240
+7.21%
華盛通- 最 高3.59
- 今 開3.38
- 成交量 276.62万股
- 最 低 3.36
- 昨 收 3.33
- 總市值 5.89亿
- 52周最高 3.9099
- 市盈率 靜 9.49
- 換手率 1.68%
- 52周最低 0.40
- 委 比 -98.51%
- 總股本 1.65亿
- 歷史最高 35.00
- 量 比 1.74
- 振 幅 6.91%
- 歷史最低 0.40
- 每 手 1
- 風險率 0.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
CytomX Therapeutics, a leader in conditionally activated biologics, will announce its third-quarter 2025 financial results on November 6 after U.S. markets close. A conference call and webcast will follow at 5:00 p.m. ET / 2:00 p.m. PT. Access the webcast via CytomX’s website or register beforehand. The company, focused on localized cancer therapies, features a PROBODY platform with candidates like CX-2051 and CX-801. For more info, contact Chris...
10-30 12:00
美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
CytomX Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
During the last three months, 4 analysts shared their evaluations of CytomX The...
10-22 05:01
Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $6
Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and raises the price target from $3.5 to $6.
10-21 19:50
CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer
CytomX Therapeutics appoints Rachael Lester as Senior Vice President and Chief Business Officer to enhance strategic planning and business development, driving advancements in cancer therapies through the company's PROBODY platform.
10-20 20:05
美股牛股 | 中概“妖股”恒峰科技上市累涨640%！锂矿股Lithium再涨22%，特朗普政府拟购买10%股权
中概股“妖股”恒峰科技上市累涨640%！公司在香港提供管理咨询、资产管理服务；锂矿股Lithium再涨22%，特朗普政府拟购买10%股权>>
09-26 17:08
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Cantor Fitzgerald Initiates Coverage On CytomX Therapeutics with Overweight Rating, Announces Price Target of $6
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on CytomX Therapeutics (NASDAQ:CTMX) with a Overweight rating and announces Price Target of $6.
09-22 20:26
New York governor seeks federal help to speed up nuclear expansion
New York Governor Kathy Hochul is urging the federal government to speed up the approval process for new nuclear energy projects as the state confronts growing electricity demand, particularly from AI...
09-11 04:33
Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV’s 8th AVG and 3rd IMRP 2025 Meeting
Cidara Therapeutics will present two oral abstracts at the ISRV/IMRP conference in Singapore, September 17-20, 2025. The late-breaking presentation, "NAVIGATE: Phase 2b Trial of CD388 for Influenza Prevention," by Dr. Rick Bright will discuss trial results on healthy adults. Additionally, Dr. Andreev Konstantin will present "Single Dose of CD388 Protects Against H5N1 in Ferret Model" in a parallel session. CD388, Cidara's lead DFC candidate, aims...
09-03 12:00
